Soligenix shareholders approve more authorized shares and reverse split authority
On September 17, 2026, Soligenix stockholders approved raising authorized common shares from 75,000,000 to 125,000,000 and gave the board up to one year to carry out a reverse stock split at a ratio between 1-for-2 and 1-for-20. Stockholders also elected five directors and chose annual advisory votes on executive compensation. Separately, the company increased its at-the-market share sale program with Rodman & Renshaw LLC by $2,500,000, which could add dilution for shareholders.
Key points
- Authorized common shares rose from 75,000,000 to 125,000,000, effective September 17, 2026 on filing with Delaware.
- Board may effect a reverse split of 1-for-2 to 1-for-20 within up to one year, with the ratio set at its discretion.
- Five directors elected, including Christopher J. Schaber, PhD, with 2,819,961 votes for; stockholders chose annual advisory votes on executive pay.
- At-the-market sales program increased by $2,500,000; about $6,234,000 had been sold under prior supplements covering up to $6,406,000.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 21, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.